Company intelligence / Profile preview

Helsinn Therapeutics

Lugano, Ticino, Switzerlandhelsinn.com ↗

Ownership: Private
Employees: ~401
Development stage: Commercial

Overview

Helsinn has multiple approved products including AKYNZEO for CINV, VALCHLOR, and Anamorelin (approved in Japan). The company has a growing pipeline of oncology and supportive care products, with several in late-stage development.

Therapeutic areas: OncologyCardiovascularNephrology
Modalities: Small molecule drugsSynthetic peptides
Industry: Biotech

Drug pipeline

1 asset

ipamorelin

Partnerships

BridgeBio PharmaTaiho Pharmaceutical Co., Ltd.AnaCardio

Beyond the preview

Go deeper on Helsinn Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helsinn Therapeutics.

Explore the full profile